

New Retinopathy of prematurity guidelines


By Dr Zola Ncube


- Definition of retinopathy of prematurity
- Physiology & pathophysiology
- ROP screening program and recent updates
- Classification of retinopathy of prematurity
- Screening procedure
- Summary and conclusion


Outline of the talk

- Developmental vascular proliferative disorder that occurs in the retina of preterm infants
- Recognized as an avoidable cause of blindness in children

What is
Retinopathy
Of
Prematurity?







- All preterm infants <31 weeks gestation
- Consider screening infants 31+ 0 – 6days (changed)
- Neonates <1501g (unchanged)

Who to screen for retinopathy of prematurity



≤ 1500g

- <30 weeks
- 1500g 2000g or > 30 weeks at risk
 - Hypotension + inotropes
 - O2 supplementation
 - O2 without monitoring



UK 2024

Roya lCollege of Pediatrics and Child health + Ophthalmologist + perinatal medicine

- Who?
 - <31 weeks gestation
 - Or <1501g
 - 31 + 0weeks 6 weeks considered (low grade)



- 34 weeks
- >34weeks + risk factors
- Birthweight >2000g when?
- Before DC from NICU
- Or by 30 weeks (whichever is first)





2013 ROP South African working group

- <32
- <1500g
- 1500 -2000 g + risk factors

Van de Lecq et al (2025)

1 May 2022 and 31 January 2023, 1879 infants were born in the region who fulfilled the GA or BW criteria for screening, that is, GA<32 completed weeks, or BW<1250 g Maximum stage of ROP in infants screened for ROP (n =696), by gestational age and birth weight





- <31 weeks: Whichever is later
 - 31 + 0 to 31 +6 PMA
 - 4 weeks PNA
- ≥ 31 weeks: Whichever is sooner
 - 36 +0 and 36+6 PMA
 - 4 weeks PNA

When to screen for retinopathy of prematurity

All infants <31 weeks gestation All infants <1501g Infants 31 + 0 weeks to 31 + 6 days

| Gestational age (weeks) | Post-menstrual age (weeks) | Post-natal age (weeks) |
|---------------------------|----------------------------|------------------------|
| 22 | 31 | 9 |
| 23 | 31 | 8 |
| 24 | 31 | 7 |
| 25 | 31 | 6 |
| 26 | 31 | 5 |
| 27 | 31 | 4 |
| 28 | 32 | 4 |
| 29 | 33 | 4 |
| 30 | 34 | 4 |
| 31 | 36 | 4 |
| 32 (birth weight <1501g) | 36 | 4 |
| 33 (birth weight < 1501g) | 36 | 3 |
| 34 (birth weight <1501g) | 36 | 2 |
| 35 (birth weight < 1501g) | 36 | 1 |

- Limited examination without an eyelid speculum and scleral indentor
- Postpone
- Counsel parents and caregivers
 - Rationale
 - Its implications
 - Next steps in screening
 - · Record discussion in the file
- Reschedule no later than one week beyond intended examination

- Apnoea's
- Bradycardia (oculocardiac reflex)
- tachycardia
- Pain
- Desaturations
- Hypertension
- Feed intolerance


What if the baby is too unstable to be screened?

International Classification of retinopathy of

prematurity (ICROP3)

 Consensus statement created standard nomenclature for classification of retinopathy of prematurity

- Initially published 1984
- Revisited in 2005
- Currently 3rd version



Extent of retinal vascularization: Zone I, zone II, zone III


Retinopathy stage (1,2,3,4,5)

Plus disease (Plus, Pre-plus)

Categories (No ROP, mild, type -2, type-1, AROP)


Classification of ROP


| Zones | Location |
|-------|---|
| 1 | A circle of radius - twice the distance from the disc centre to the macula |
| 2 | From the edge of zone 1 to the nasal ora serrata |
| 3 | Residual crescent of retina area of the temporal retina |





Stage 1 ROP
Demarcation line

A thin but definite structure (white line) separating the avascular retina anteriorly from the posteriorly vascularised retina










Stage 5 ROP Total retinal detachment

- Retinal detachments are generally tractional but
- may occasionally be exudative,
- and are usually funnel-shaped.




Plus disease

- Dilation and tortuosity of the retinal vessels within zone 1
- Added to staging system in 2005 revision of the international classification of retinopathy of prematurity ICROP
- pre-plus disease
 - Marked than normal changes



Pre-plus disease

- Active retinopathy of prematurity
- Features insufficient for diagnosis of plus disease
- Vascular changes more marked than normal
- pre-stage which could progress to plus disease





ROP screening Program





Identify retinopathy of Prematurity and treat sight threatening ROP



- Minimizing the number of stressful examinations required for sick neonates
- Cost effective
 - Number needed to screen to identify 1 infant needing treatment is 41 (Visser et al) 2014





















2022 ICROP

Posterior zone II AR vs AP-ROP
Definition of plus disease
Set stage for AI assisted screening





2021 AAP

Advances in antiVEGF &
follow-up
recommendations
Use of telemedicine and
wide-field imaging



<=1501g
<32 weeks
Incorporated
digital imaging
Implementation
of standard
documentation



2001 AAP <1500g <30 weeks

2005 ETROP study

Type 1 & type 2 ROP for earlier treatment

2013

- Digital retinal imaging
- Emphasis on better documentation

ROP working group of South Africa 2013



Summary guidelines

- Latest guidelines from Royal College of Pediatrics & child health (RCPCH)
- Separate guideline on treatment developed by the Royal College of Ophthalmology



https://images.app.goo.gl/ZsKBE





Who to screen

Timing of first examination

Preparation for screening

Importance of follow-up examination

Guidelines on when to refer

Record keeping and communication

Algorithm for observations and screening record form

Summary of Updates

- Equipment
- Preparation
- Procedure
- Treatment
- Follow-up plan
- Recording of findings
- System
- Counseling of care givers

Screening procedure





Screening exam techniques

Binocular indirect ophthalmoscopy



Wide field digital imaging



- Resuscitation equipment
- Monitor
 - Blood pressure
 - Heart rate
 - Respiratory rate
- Eyelid speculum and scleral indentor
 - Visualize the peripheral retina
 - Indentor is used gently to rotate the eye





Infection control and preventative measures

- Sterilize all reusable instruments
- Disinfect the lenses as per hospital policy and manufacturer
- Or use single use instruments



Preparation for the exam

- Mydriatic combination
 - Phenylephrine 2.5 % + cyclopentolate 0.5%
 - Cyclomidril
 - 1 drop in 2 doses
 - 1hr prior
 - 5 minutes apart
 - Tropicamine 0.5 % (alternative to cyclopentolate 0.5% shorter duration of action)
- Topical anesthetic
 - Proxymetacaine 0.5%
 - Oxybuprocaine 0 4% (shorter duration of action)



Pain relief & comfort care during procedure

- Topical anesthetic
 - Proxymetacaine 0.5%
 - Oxybuprocaine 0.4% (shorter duration)
- Non-pharmacological
 - Nesting
 - Cuddling
 - Non-nutritive suck
 - Giving expressed breastmilk
 - Oral sucrose



- Extent of vascularization by zone in the absence of ROP
- Zone and stage of ROP
- Extent of ROP stage in clock hours
- Presence and extent in quadrants of any pre-plus or plus disease
- Name of the examiner
- Date of the next examination or discharge from screen
- All communications should be documented
- Can be done documented electronically or on paper compatible with the international classification of ROP.

Record keeping and communication

| Name: | | Gestational | Gestational age (wks): | | | | | | |
|------------------------|--|---------------------------------------|---|-----------------|--|--|--|--|--|
| Hospital No: | | Birth Weight (g): | | | | | | | |
| DoB: | Male/Female | Previous sc | Previous screening? Y/N Hospital: | | | | | | |
| | | Previous tre | Previous treatment? Y/N Type: | | | | | | |
| Stage 1 | Stage 2 | Stage 3 | Stage 4/5 | ×××× | | | | | |
| Date of examination: | R | | L | | | | | | |
| Name of examiner: | /111/11 | | | m in the second | | | | | |
| Postmenstrual age: | | | | · PIT | | | | | |
| Findings: | 1 1 6 | | 1 / | 911 | | | | | |
| Progression | The state of the s | | | | | | | | |
| Regression No change | *************************************** | | | | | | | | |
| Follow up: | Zone: Stage: | A-ROP: Y/N | Zone: Stage: | A-ROP: Y/N | | | | | |
| Refer: Y/N | Zone I/posterior zone I notch: Y/N Plus: Y/ | II due to temporal N Pre-plus: Y/N | Zone I/posterior zone II due to temporal notch: Y/N Plus: Y/N Pre-plus: Y/N | | | | | | |

Assessment

No ROP

- The retina is not completely vascularised until 40 weeks gestation
- Premature infants may have immature retinal vessels without having ROP.

Mild ROP


- Presence of ROP that is at low risk for requiring treatment
- Low stage
- Peripheral retina where it is unlikely to affect the visual axis
- Zone II, stage 1 or 2 (without plus disease)
- Zone III, any stage (without plus disease)

The early treatment for retinopathy of prematurity (ETROP) trial

Type 2

- Requires close follow-up
- Not severe enough to require treatment
- Zone 1, stage 1 or 2 without plus disease
- Zone II, stage 3 without plus disease


- Type- 1 ROP
 - Severe disease needing treatment within 48 hrs
 - Zone I, any stage with plus disease
 - Zone 1, stage 3 without plus disease
 - Zone II, stage 2 or 3 with plus disease



Natural course ICROP & CRYO ROP trial

7 – 10 % develop threshold ROP

85 % will spontaneously regress



Treatment of retinopathy of prematurity

https://images.app.goo.gl/MtqwT

https://images.app.goo.gl/hjRas

Regression

- New ICROP3
- Disease involution and resolution
 - Complete or incomplete
- Persistent avascular retina

Reactivation

- Recurrence of acute phase features of ROP
- Typically, ~37 60 weeks or later
- Common after antiVEGF >laser

Why should we followup? What is the big deal?



https://images.app.goo.gl/t MHr9



https://images.app.goo.gl/sHoQV



https://images.app.goo.gl/j mwd6



https://images.app.goo.gl/ZiY Xi



https://images.app.goo.gl /iisxe



https://images.app .goo.gl/ZcxPv



https://images.app.g oo.gl/eeS4c

Algorithm for ophthalmic observations

Observations at each screening examination should determine the appropriate course of action. The ICROP revisited definition of zones of the retina, stage of disease and pre-plus should be used.

| Presence of ROP | N | 0 | Less Severe | | | | | | More Severe | | | | | |
|-----------------------------------|---|-----------------------|--------------------------------------|---|----------------------------|--|---------------|--------------------|------------------------------|------------------------------|----------------|------------|-----------|-------|
| ROP zone or vessel location | П | ī | II or III | II or III | T | ī | II or III | II or III | II or III | ii | Ü | Ť | 24 | A-ROP |
| ROP Stage | 1#1 | e. : e: | 1 or 2 | 1 or 2 | 1 or 2 | 1 or 2 | 3 | 3 | ANY | 2 | 3 | 3 | ANY | ANY |
| Plus/ Pre- plus disease | 80 | | None | Pre-plus | None | Pre-plus | None | Pre-plus | Plus | Plus | Plus | None | Plus | Plus |
| Screening Frequency | Every 2 weeks | Every week | Every 2 weeks | Every week | Every week | At least weekly | Every week | At least weekly | At least weekly | At least weekly | Not applicable | | | |
| Contact network treater | No | No | No | No | No | Yes (Discuss*) | No | Yes (Discuss*) | Yes (Possibly treat**) | Yes (Possibly treat**) | Yes (Treat) | | | |
| When to treat (if required) | 48 – 72 hours | | | | | | | | | Within 48 hours | | | | |
| When to discontinue screening | If no ROP observed: Vessels pro to zone III o >36+0 wee | ogressed or infant | examinat - partial re - change | ions: esolution pro in colour of i | ogressing t the ridge f | scontinue se towards com rom salmon demarcation | plete reso | lution | cteristics of | regression | are obser | ved on 2 s | uccessive | |

Notes: Posterior Zone II (as defined by ICROP3) should be regarded as equivalent to Zone I. Plus disease should be present in 2 or more quadrants; Plus disease limited to one quadrant should be regarded as pre-plus.

*Discuss: phone discussion with network treater (and share images if available).

**Possibly treat: phone discussion with network treater (and share images if available) with a view to probable transfer of infant for possible treatment.

Counseling Parents/caregivers

Explain whyCounselling

Need for screening

Transfer / discharge checklist

Long term outcome

Potential for development of refractive errors or strabismus later

Written information/ pamphlet Implications for missed appointments
Risk of not detecting progression



Telephone and written communication









Service configurations



Uninterrupted service



Ophthalmologist- knowledge, skill and competency



Standard operating procedure

 Safe and timely treatment onsite or transfer

Protocol



Role players:

- Scheduling first and follow-up
- Responsible for treatment



Record keeping, stores, equipment and its maintenance





SOP, audit recommendations for quality of service

Take home message

- ROP is one of the preventable cause of blindness
- Screening is important to identify infants at risk for severe disease
 - Definitively screen infants <31 weeks or <1500g at 31 weeks PMA or 4 weeks of life
 - ≤32 weeks can be screened at 36 weeks PMA or 4 weeks PNA whichever is ealiest
- Counselling and documentation
 !!!!!!!

Take home message TTO

References

- https://www.rcpch.ac.uk/sites/default/files/2024-10/rop-screening-guideline-full-2022_updated-2024.pdf
- L Visser, R Singh, M Young, H Lewis, N McKerrow (ROP Working Group, South Africa) Guideline for the prevention, screening and treatment of retinopathy of prematurity (ROP) S Afr Med J 2013;103(2):116-125. DOI:10.7196/SAMJ.6305
- Jang, J.H., Kim, Y.C. Retinal vascular development in an immature retina at 33–34 weeks postmenstrual age predicts retinopathy of prematurity. Sci Rep 10, 18111 (2020). https://doi.org/10.1038/s41598-020-75151-0
- Lai Y-H, Chen H-L, Yang S-N, Chang S-J, Chuang L-Y, Wu W-C (2018) The characteristics of premature infants with transient corneal haze. PLoS ONE 13(3): e0195300. doi:10.1371/journal.pone.0195300
- Mintz-Hittner, Helen & Kennedy, Kathleen & Chuang, Alice. (2011). Efficacy of Intravitreal Bevacizumab for Stage 3+ Retinopathy of Prematurity. The New England journal of medicine. 364. 603-15. 10.1056/NEJMoa1007374.
- Hong, E.H., Shin, Y.U., Bae, G.H. et al. Ophthalmic complications in retinopathy of prematurity in the first decade of life in Korea using the national health insurance database. Sci Rep 12, 911 (2022). https://doi.org/10.1038/s41598-021-04616-7

THANK YOU
FOR YOUR
ATTENTION